CTS has been demonstrated to be a potent antitumor agent due to its ability to induce cell death and apoptosis in human lung carcinoma A549 (A549/DDP) cells and enhance the sensitivity of cisplatin by down-regulating Nrf2 pathway 97. The gene discussed is NFE2L2; the disease is lung carcinoma.